Systemic inflammation score as a preoperative prognostic factor for patients with pT2-T4 resectable gastric cancer: a retrospective study.
Gastric cancer
Prognostic factor
Systemic inflammation score
Journal
BMC surgery
ISSN: 1471-2482
Titre abrégé: BMC Surg
Pays: England
ID NLM: 100968567
Informations de publication
Date de publication:
12 Jan 2023
12 Jan 2023
Historique:
received:
31
03
2022
accepted:
04
01
2023
entrez:
12
1
2023
pubmed:
13
1
2023
medline:
17
1
2023
Statut:
epublish
Résumé
Systemic inflammation has been reported to be associated with cancer progression and metastasis. Systemic inflammation score (SIS), calculated from preoperative serum albumin level and lymphocyte-to-monocyte ratio, has been shown to be a novel prognostic factor for several types of tumors. This study aimed to evaluate the prognostic value of the SIS in patients with pT2-4 resectable gastric cancer (GC). Total 97 patients with pT2-4 GC who underwent curative surgery from 322 cases between 2009 and 2015 in Fukushima Medical University Hospital were included. We performed univariate and multivariate analyses to evaluate the usefulness of preoperative SIS and other prognostic factors for relapse-free survival (RFS) and overall survival (OS). The higher SIS score was associated with undifferentiated cancer and recurrence. Univariate analysis of RFS identified deeper tumor invasion and higher SIS were significant risk factors and multivariate analysis revealed that both of them were independent prognostic factors for RFS. As for OS, age, tumor invasion, SIS and LNR were significantly correlated with RFS. In multivariate analysis, tumor invasion, SIS and LNR were independent prognostic factors for OS. SIS was an independent prognostic factor for RFS and OS in pT2-4 resectable gastric cancer patients who underwent curative gastrectomy.
Sections du résumé
BACKGROUND
BACKGROUND
Systemic inflammation has been reported to be associated with cancer progression and metastasis. Systemic inflammation score (SIS), calculated from preoperative serum albumin level and lymphocyte-to-monocyte ratio, has been shown to be a novel prognostic factor for several types of tumors. This study aimed to evaluate the prognostic value of the SIS in patients with pT2-4 resectable gastric cancer (GC).
METHODS
METHODS
Total 97 patients with pT2-4 GC who underwent curative surgery from 322 cases between 2009 and 2015 in Fukushima Medical University Hospital were included. We performed univariate and multivariate analyses to evaluate the usefulness of preoperative SIS and other prognostic factors for relapse-free survival (RFS) and overall survival (OS).
RESULTS
RESULTS
The higher SIS score was associated with undifferentiated cancer and recurrence. Univariate analysis of RFS identified deeper tumor invasion and higher SIS were significant risk factors and multivariate analysis revealed that both of them were independent prognostic factors for RFS. As for OS, age, tumor invasion, SIS and LNR were significantly correlated with RFS. In multivariate analysis, tumor invasion, SIS and LNR were independent prognostic factors for OS.
CONCLUSIONS
CONCLUSIONS
SIS was an independent prognostic factor for RFS and OS in pT2-4 resectable gastric cancer patients who underwent curative gastrectomy.
Identifiants
pubmed: 36635689
doi: 10.1186/s12893-023-01904-z
pii: 10.1186/s12893-023-01904-z
pmc: PMC9837917
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
8Informations de copyright
© 2023. The Author(s).
Références
Ann Surg. 2018 Mar;267(3):527-531
pubmed: 27984214
Br J Cancer. 2010 Nov 23;103(11):1649-56
pubmed: 21063409
Br J Cancer. 2017 Nov 21;117(11):1583-1591
pubmed: 29065107
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
ANZ J Surg. 2019 Apr;89(4):377-382
pubmed: 30854753
Cancer Cell. 2015 Apr 13;27(4):462-72
pubmed: 25858805
Int J Colorectal Dis. 2007 Aug;22(8):881-6
pubmed: 17245566
Curr Opin Clin Nutr Metab Care. 2009 May;12(3):223-6
pubmed: 19318937
Ann Surg Oncol. 2010 Nov;17(11):2847-55
pubmed: 20559741
Clin Chim Acta. 2020 Dec;511:81-89
pubmed: 33002476
Int J Surg. 2018 Sep;57:76-83
pubmed: 30103072
J Nippon Med Sch. 2021 Jun 30;88(3):156-162
pubmed: 33692288
Nature. 2009 Jan 1;457(7225):36-7
pubmed: 19122629
Nat Rev Cancer. 2010 Jan;10(1):2-3
pubmed: 20050335
Dig Surg. 2020;37(5):401-410
pubmed: 32344400
Ann Surg. 2017 Mar;265(3):539-546
pubmed: 27070934
Cochrane Database Syst Rev. 2010 Mar 17;(3):CD004064
pubmed: 20238327
J Gastroenterol. 2014 Jun;49(6):1040-6
pubmed: 23821018
Carcinogenesis. 2009 Jul;30(7):1073-81
pubmed: 19468060
Nutr Cancer. 2015;67(8):1260-7
pubmed: 26583916
J Surg Res. 2016 May 15;202(2):284-90
pubmed: 27229102
Br J Cancer. 2015 Aug 11;113(4):626-33
pubmed: 26135896
Anticancer Res. 2020 Mar;40(3):1503-1512
pubmed: 32132050
Ann Surg Oncol. 2015 Jan;22(1):302-10
pubmed: 24952029
World J Surg. 2018 Oct;42(10):3277-3285
pubmed: 29560531
World J Surg. 2018 Jun;42(6):1819-1825
pubmed: 29270656
Nature. 2008 Jul 24;454(7203):436-44
pubmed: 18650914
PLoS One. 2016 Dec 8;11(12):e0167967
pubmed: 27930703
Med Sci Monit. 2019 Jun 11;25:4342-4352
pubmed: 31182704
N Engl J Med. 2008 Jul 31;359(5):453-62
pubmed: 18669424
Int J Radiat Oncol Biol Phys. 2009 Jul 1;74(3):796-802
pubmed: 19289261
J Cell Physiol. 2013 Jul;228(7):1404-12
pubmed: 23065796
Lancet Oncol. 2014 Oct;15(11):e493-503
pubmed: 25281468